Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.
Seed Therapeutics
Series A in 2024
Seed Therapeutics is a biotechnology company that specializes in the research and development of medical drugs aimed at treating severe diseases. The company focuses on harnessing and engineering molecules, specifically utilizing molecular glues to target proteins that were previously considered undruggable. By creating novel protein degradation therapeutics, Seed Therapeutics aims to positively disrupt cancer biology, offering potential benefits to patients across various tumor types.
RecoMed
Corporate Round in 2024
RecoMed is South Africa's largest online healthcare booking platform, designed to connect patients with healthcare providers efficiently. Its core offering is a user-friendly online booking system that allows patients to find and schedule appointments with various healthcare professionals at any time, eliminating the need for phone calls or paperwork. In addition to serving individual consumers, RecoMed has developed white-labelled solutions for notable organizations, enhancing its presence in the healthcare ecosystem. The platform facilitates real-time connections between doctors and patients, contributing to improved patient experiences and enabling healthcare professionals to expand their practices. RecoMed effectively operates within the broader healthcare, life insurance, and corporate wellness sectors, positioning itself as a significant player in the marketplace.
C2N Diagnostics
Corporate Round in 2024
C2N Diagnostics, LLC is a privately held company focused on protein diagnostics and therapeutic discovery for progressive neurodegenerative diseases, particularly Alzheimer's disease. Founded in late 2007 by Drs. David Holtzman and Randall Bateman from Washington University School of Medicine, alongside LifeTech Research, the company is based at the Center for Emerging Technologies in St. Louis. C2N Diagnostics utilizes advanced mass spectrometry techniques to offer precise identification, quantification, and monitoring of proteins and biomolecules associated with neurological disorders. This innovative approach enables healthcare professionals to detect and characterize neurocognitive disorders more accurately, enhancing the potential for effective diagnosis and treatment strategies.
Hyku is a biotechnology company focused on developing small molecule therapeutics that target disease-causing proteins through precise covalent binding. Utilizing its innovative platform, Hyku identifies molecules that covalently bind to non-cysteine amino acids, facilitating the creation of novel therapies. These therapies aim to address significant challenges in drug development, including issues related to selectivity, druggability, and resistance. By pushing the boundaries of covalent medicine, Hyku seeks to create effective treatments that can improve patient outcomes and advance the field of therapeutic development.
Casma Therapeutics
Series C in 2022
Casma Therapeutics, Inc. specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy and lysosomal flux. By focusing on enhancing autophagy, the company aims to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing the progression of various diseases. Its research targets several serious medical conditions, including lysosomal storage disorders, muscle disorders, inflammatory disorders, and neurodegeneration. Founded in 2017 and based in Cambridge, Massachusetts, Casma Therapeutics is dedicated to creating effective treatment options that meet significant unmet medical needs in the field of drug discovery and development.
Lifenet Insurance
Post in 2022
Lifenet Insurance Company is a Tokyo-based firm that specializes in providing life insurance products and services in Japan. Founded in 2006, the company offers a diverse range of insurance solutions, including term death insurance, whole life medical insurance, cancer insurance, and disability insurance. Lifenet distinguishes itself by selling its products directly to consumers through the internet, facilitating easy access to its offerings. In addition to insurance underwriting, the company also engages in asset management and provides health counseling services, aiming to meet the varied needs of its customers in the life insurance sector.
Tacit Therapeutics
Venture Round in 2022
Tacit Therapeutics is a biotechnology company focused on developing RNA-targeted treatments to address genetic diseases. Founded in 2021 and based in South San Francisco, California, the company utilizes pre-existing components of human cells to create innovative, non-immunogenic methods for repairing mutated genes. By offering a broadly applicable approach to gene modification, Tacit Therapeutics aims to provide effective solutions for genetic conditions that were previously deemed untreatable, thereby enabling advancements in the treatment of devastating diseases.
Arteryex
Acquisition in 2022
Arteryex specializes in the commissioned development of systems and applications within the medical and healthcare sectors. The company operates its own applications, including Pashatto Karte and the LEAF app, which supports health management for employees. Additionally, Arteryex has developed an enterprise data management platform that enhances the retrieval and sharing of medical documents. By integrating technologies like blockchain and artificial intelligence, the platform optimizes health management and medical care tailored to individual needs. This enables clients to access personal health record-related services beneficial to patients, healthcare professionals, and the broader community.
Ractigen Therapeutics
Series A in 2022
Ractigen Therapeutics is an early-stage pharmaceutical company focused on developing first-in-class therapies that aim to selectively restore the expression of therapeutic genes silenced in diseased cells. Utilizing a groundbreaking technology known as RNA activation (RNAa), which originated from research at the University of California San Francisco, Ractigen is working on a diverse pipeline of candidate medicines targeting various conditions with significant unmet medical needs. The company’s innovative approach addresses diseases related to inadequate gene expression, concentrating on key therapeutic areas such as central nervous system disorders, tumors, liver diseases, and ophthalmic conditions. By leveraging its unique technology and a portfolio of innovative patents, Ractigen strives to deliver effective treatment options to patients.
Prism BioLab
Series C in 2021
Prism BioLab is focused on drug discovery and development, utilizing its proprietary PepMetics Technology to create therapeutic agents. The company specializes in treatments for non-oncology indications, particularly targeting conditions such as pulmonary fibrosis and other incurable diseases. By leveraging its innovative platform, Prism BioLab aims to provide effective solutions for these challenging health issues.
Neuroglee Health
Series A in 2021
Neuroglee Health is a digital therapeutic platform focused on treating patients in the early stages of neurodegenerative diseases. The company develops therapeutic devices that aim to preserve cognitive function and independence for individuals facing these conditions. By utilizing cognitive and neurobehavioral mechanisms, Neuroglee's tools engage users on a personal level and provide consistent insights into the efficacy of treatments. This approach not only empowers patients in managing their health but also supports accelerated drug development through effective monitoring. Through its innovative solutions, Neuroglee Health seeks to enhance the quality of life for those affected by neurodegenerative disorders.
Sola Biosciences
Seed Round in 2021
SOLA Biosciences is focused on advancing healthcare through innovative biotechnological solutions. The company has developed a modular bioreactor named Sola, which enables users to cultivate cells effectively. In addition to this bioreactor, SOLA Biosciences is engaged in the development of transformative gene therapies aimed at treating conformational diseases. Utilizing its proprietary chaperone platform technology, the company targets neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Huntington's disease (HD). By selectively reducing abnormal, disease-causing proteins that accumulate in neuron cells, SOLA Biosciences aims to provide permanent therapeutic options for patients suffering from these debilitating conditions.
Altoida
Venture Round in 2021
Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.
Voluntis, established in 2001, specializes in developing digital therapeutic solutions for diabetes, oncology, and other therapeutic areas. The company offers products such as Insulia, Diabeo, Oleena, and AstraZeneca, which provide automated insulin dose recommendations, patient-specific dosage suggestions, and management of side effects like hypertension and diarrhea. Voluntis collaborates with pharmaceutical companies like Bristol-Myers Squibb to co-develop digital therapeutics for oncology. Headquartered in France with operations in the U.S., Voluntis aims to enhance patient outcomes and healthcare system efficiency through innovative, secure, and patient-centric digital health solutions.
Allm Inc. is a medical ICT company based in Tokyo, Japan, that focuses on enhancing healthcare communication through advanced technologies. Founded in 2001, Allm offers a variety of applications designed to facilitate communication among healthcare professionals, including Kaigo for home care workers, Kango for home care nurses, and MySOS for first-aid support and medical record management. Additionally, the company provides AcaMed, an online community aimed at advancing medical research, and FollowUP, a business intelligence system for real-time management information. Allm's solutions are utilized in over 18 countries across regions such as the US, South America, Europe, Japan, the Middle East, and Africa, contributing to improved efficiency and quality of care in community healthcare systems. The company, formerly known as SkillUpJapan Corp., rebranded to Allm Inc. in January 2015 and operates several subsidiaries globally.
Neuroglee Health
Pre Seed Round in 2020
Neuroglee Health is a digital therapeutic platform focused on treating patients in the early stages of neurodegenerative diseases. The company develops therapeutic devices that aim to preserve cognitive function and independence for individuals facing these conditions. By utilizing cognitive and neurobehavioral mechanisms, Neuroglee's tools engage users on a personal level and provide consistent insights into the efficacy of treatments. This approach not only empowers patients in managing their health but also supports accelerated drug development through effective monitoring. Through its innovative solutions, Neuroglee Health seeks to enhance the quality of life for those affected by neurodegenerative disorders.
Unlearn.AI
Series A in 2020
Unlearn.AI, Inc. is a biotechnology company that specializes in developing software tools for clinical research, focusing on improving diagnosis and treatment processes. Based in San Francisco, the company offers solutions such as Clinical Trial Design, which helps define inclusion criteria, endpoints, and study sizes; Synthetic Control Arms, which reduce or eliminate the necessity for concurrent control groups; and Subgroup Analysis, which identifies specific patient subgroups within trial results. Unlearn.AI has pioneered the TwinRCT solution, a digital twin service that leverages machine learning to enhance the efficiency and success rates of clinical trials. This innovative approach creates a prognostic digital twin for each patient, allowing for more precise estimations of treatment effects based on historical data. By integrating machine learning and biostatistics, Unlearn.AI aims to accelerate the clinical trial process, benefiting both patients and pharmaceutical sponsors.
Darmiyan
Seed Round in 2020
Darmiyan, Inc. is a company that specializes in the development of diagnostic software aimed at the early detection and monitoring of Alzheimer's disease and other neurodegenerative disorders. Based in San Francisco and founded in 2014, the company offers BrainSee, a Software as a Service platform that utilizes non-invasive brain MRI scans to produce detailed brain maps. This innovative tool quantifies neurodegeneration in individual brain voxels and generates a summary score reflecting brain health and the risk of cognitive decline. BrainSee operates using proprietary technology, referred to as The Virtual Microscope, which provides insights into brain cell distortion before clinical symptoms manifest. The algorithm has undergone successful third-party validation in the US and Canada, demonstrating its accuracy in predicting mild cognitive impairment. By leveraging advanced medical imaging and artificial intelligence, Darmiyan aims to enhance early diagnosis and intervention for patients with neurodegenerative diseases.
Caraway Therapeutics
Venture Round in 2020
Caraway Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases through the modulation of mitophagy and autophagy. By targeting genetically defined pathways, the company aims to create small molecules that restore cellular balance and address the underlying mechanisms of diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Founded in 2018 and based in Cambridge, Massachusetts, Caraway Therapeutics seeks to improve the lives of patients affected by these debilitating conditions by leveraging its expertise in cellular degradation processes. The company was previously known as Rheostat Therapeutics, Inc. before rebranding in October 2019.
Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.
Allm
Corporate Round in 2019
Allm Inc. is a medical ICT company based in Tokyo, Japan, that focuses on enhancing healthcare communication through advanced technologies. Founded in 2001, Allm offers a variety of applications designed to facilitate communication among healthcare professionals, including Kaigo for home care workers, Kango for home care nurses, and MySOS for first-aid support and medical record management. Additionally, the company provides AcaMed, an online community aimed at advancing medical research, and FollowUP, a business intelligence system for real-time management information. Allm's solutions are utilized in over 18 countries across regions such as the US, South America, Europe, Japan, the Middle East, and Africa, contributing to improved efficiency and quality of care in community healthcare systems. The company, formerly known as SkillUpJapan Corp., rebranded to Allm Inc. in January 2015 and operates several subsidiaries globally.
iPS PORTAL
Venture Round in 2015
iPS PORTAL, Inc., founded in 2014 and based in Kyoto, Japan, specializes in the development of instruments for analyzing and measuring cells. The company focuses on contract testing of induced pluripotent stem (iPS) cells, aiming to promote the widespread adoption of iPS cell technology. iPS PORTAL provides research and development outsourcing services that support the practical application of iPS cell technology. Its offerings include assistance in research, contract testing, development, concept planning, and training programs in cell culture for researchers. By facilitating these services, iPS PORTAL enables healthcare companies to enhance research efforts and expedite the commercialization of drug discovery and regenerative medicine.
AkaRx, Inc., a biopharmaceutical company, develops therapeutic treatments for unmet medical needs. Its product includes AKR-501, an orally-available small molecule for use in the treatment of thrombocytopenia. The company was founded in 2005 and is headquartered in Paramus, New Jersey.
SymBio Pharmaceuticals
Venture Round in 2009
SymBio Pharmaceuticals Limited is a biopharmaceutical company based in Tokyo, Japan, focused on the research, development, manufacturing, and marketing of pharmaceutical drugs, primarily in the fields of oncology and hematology. The company develops various anti-cancer agents, including Treakisym, which is used to treat non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia, and is currently undergoing Phase III trials for relapsed/refractory diffuse large B-cell lymphoma. Additionally, SymBio is working on several other drug formulations, including SyB L-1701, SyB L-1702, and Rigosertib SyB-C-0501, as well as SyB L-1101 and SyB C-1101 for higher-risk myelodysplastic syndromes. The company also has a candidate, SyB V-1901, aimed at treating infectious diseases. SymBio Pharmaceuticals operates primarily in Japan, South Korea, China, Hong Kong, Taiwan, and Singapore.
MGI Pharma
Acquisition in 2008
MGI PHARMA, INC., a biopharmaceutical company, engages in the acquisition, research, development, and commercialization of pharmaceutical products for oncology and acute care applications. The company markets its products through sales organizations in the United States, as well as alliances with other pharmaceutical or biotechnology companies internationally. MGI PHARMA, INC. was founded in 1979 as Molecular Genetics, Inc. and changed its name to MGI PHARMA, INC. in 1990. The company is headquartered in Bloomington, Minnesota. It has facilities in Bloomington, Minnesota; Lexington, Massachusetts; and Baltimore, Maryland. As of January 25, 2008, MGI PHARMA, INC. operates as a subsidiary of Eisai Corporation of North America.
Morphotek
Acquisition in 2007
Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.